Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Mallinckrodt
Moodys
Colorcon
McKesson

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for substance P


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug substance P?

substance P is an investigational drug.

There have been 9 clinical trials for substance P. The most recent clinical trial was a Phase 1 trial, which was initiated on November 15th 2018.

The most common disease conditions in clinical trials are Heart Diseases, Hypertension, and Vascular Diseases. The leading clinical trial sponsors are University of Edinburgh, NHS Lothian, and Vanderbilt University.

There are eleven US patents protecting this investigational drug and two hundred and ninety international patents.

Recent Clinical Trials for substance P
TitleSponsorPhase
Substance P Challenge in Healthy ParticipantsGlaxoSmithKlineN/A
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1Vanderbilt University Medical CenterPhase 4
Neuropeptide Therapy of Recent Onset Type 1 DiabetesVanilloid Genetics Inc.Phase 1

See all substance P clinical trials

Clinical Trial Summary for substance P

Top disease conditions for substance P
Top clinical trial sponsors for substance P

See all substance P clinical trials

US Patents for substance P

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
substance P ⤷  Try it Free NK3 agonist for use in the treatment of a patient suffering from atrial arrhythmia or fibrillation Academisch Medisch Centrum (Amsterdam, NL) ⤷  Try it Free
substance P ⤷  Try it Free Non-crosslinked protein particles for therapeutic and diagnostic use Hemosphere, Inc. (Irvine, CA) ⤷  Try it Free
substance P ⤷  Try it Free Non-crosslinked protein particles for therapeutic and diagnostic use Hemosphere, Inc. (Irvine, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for substance P

Drugname Country Document Number Estimated Expiration Related US Patent
substance P World Intellectual Property Organization (WIPO) WO2014169250 2033-04-11 ⤷  Try it Free
substance P World Intellectual Property Organization (WIPO) WO2014169250 2033-04-11 ⤷  Try it Free
substance P European Patent Office EP3206702 2034-10-16 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Mallinckrodt
Moodys
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.